Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 16, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 275,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,430.9 pence per share.
- Treasury Shares Held: 294,947,678 shares (representing 4.90% of total voting rights).
- Shares in Issue: 5,725,094,909 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 275,000 shares on May 16, 2007. These shares are intended to be held in Treasury. The filing does not disclose changes in operating performance or financial position compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (294,947,678) against the company's latest capitalization table.
- Confirm the percentage of total voting rights represented by Treasury shares (4.90%).
- Check the total number of shares in issue (5,725,094,909) for use in calculating shareholder notification thresholds under Disclosure and Transparency Rules.
- Review the Annual General Meeting minutes from May 17, 2006, to confirm the scope of the share repurchase authority utilized.